Recent Updates
Recently added Catalysts
PRAX Positive Sentiment Score: 70/100

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Key Takeaway: Praxis Precision Medicines will report its Q1 2026 financial results on May 7, 2026, and provide a corporate update. The company will also participate in the Bank of America Securities Health Care Conference on May 12, 2026. The live webcast of both events will be accessible through their website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Praxis will report its financial results and provide a corporate update.
  • The company is actively participating in an upcoming investor conference.
  • Praxis has a diversified CNS portfolio with multiple late-stage product candidates.

Full Press Release Details

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and provide a corporate update before the financial markets open on Thursday, May 7, 2026.
The Company will host a conference call and a live webcast to review the first quarter financial results and provide a corporate update on Thursday, May 7, 2026, at 8:30 am ET, which can be accessed by visiting thisregistration link. The live webcast will also be available on theEvents & Presentationspage of the Investors + Media section of the company’s websitewww.praxismedicines.com.
In addition, Praxis will be attending and presenting at the Bank of America Securities Health Care Conference. A corporate presentation will take place on Tuesday, May 12, 2026, at 7:20 pm EDT (4:20 pm PDT) at the Encore at the Wynn Hotel in Las Vegas, NV. A live webcast of the presentation will be availablehere. A replay of the webcast will be available after the event for approximately 90 days.
About PraxisPraxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us onFacebook,Instagram,LinkedInandTwitter/X.

Frequently Asked Questions

When will Praxis report its Q1 2026 financial results?

Praxis will report its Q1 2026 financial results on May 7, 2026.

What time is the conference call for Q1 results?

The conference call will take place at 8:30 am ET on May 7, 2026.

Where can I access the live webcast?

The live webcast can be accessed on the company's website under Events & Presentations.

When is Praxis presenting at the investor conference?

Praxis will present at the Bank of America Securities Health Care Conference on May 12, 2026.

Last updated: May 4, 2026